Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics

Toshihiro Inokuchi, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, Tsuyoshi Fujimoto, Reiji Higashi, Yuki Morito, Toru Nawa, Seiyuu Suzuki, Mamoru Nishimura, Masafumi Inoue, Jun Kato, Hiroyuki Okada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Fingerprint Dive into the research topics of 'Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics'. Together they form a unique fingerprint.

Medicine & Life Sciences